Application Notes

Exbumin – Stabilizing Virus with Albumin to Improve Yield Application Note

Expansion of Adherent HEK293T Cells in Flasks in Chemically Defined Cell Culture Media

Lentivirus Production Protocol in Serum-Free Conditions – How To Improve Transfection Efficiency and Titer Yield

OptiVERO – Virus Production Using VERO Cells in Flasks without Serum in Chemically Defined Cell Culture Media Application Note

OptiVERO – Virus Production Using VERO Cells with Microcarriers Without Serum in Chemically Defined Cell Culture Media

Blog

Evolving Challenges in Closed-System Biomanufacturing

How Regulatory Bodies Are Driving the Shift to Animal-Origin-Free Solutions in Cell Therapy and Vaccine Development

Innovative Solutions in Closed-System Biomanufacturing: Exploring the Tools and Technologies Driving Sterility and Efficiency

Optibumin vs Traditional Albumin: Comparing Performance in Cell Wash Applications

SARS-CoV2 and Influenza – Double Threat

Scaling Innovation: How DiscGenics and InVitria are Leading the Future of Cell Therapy

Solving the Vaccine Supply Challenge

Journal Articles (DOI Links)

Formulation and Production of a Blood-free and Chemically Defined Virus Production Media for VERO Cells

Posters

Addressing Vaccine Stability And Cold Chain Challenges With Recombinant Human Serum Albumin To Enable Global Administration

Advancing Vaccine Excellence

Product Brochures

ITSE AF – Brochure

Optiferrin – Product Brochure

Product Specifications

ITS – Specifications

SDS

Exbumin – Safety Data Sheet

ITSE AF – Safety Data Sheet

Use Guidelines

Exbumin – Guidelines for Use

ITS – Guidelines for Use

ITSE AF – Guidelines for Use

ITSE+A – Guidelines for Use

OptiVERO – Guidelines for Use

Webinar

Accelerating Vaccine Development Through Use of Blood-Free Components

White Papers

Cellastim S – Recombinant Human Serum Albumin in the Generation of Functional Cardiomyocytes from Pluripotent Stem Cells

Emergence of Blood-Free Recombinant Human Albumin

Optimizing the Performance of LNP and Liposome Therapeutics with Blood-Free Recombinant Albumin

VERO Expansion in the iCellis® Bioreactor with Chemically Defined and Blood Free Virus Production Media